Efficacy and safety of three-times-daily versus twice-daily biphasic insulin aspart 30 in patients with type 2 diabetes mellitus inadequately controlled with basal insulin combined with oral antidiabetic drugs


Yang W., ERSOY C., Wang G., Ye S., Liu J., Miao H., ...More

DIABETES RESEARCH AND CLINICAL PRACTICE, vol.150, pp.158-166, 2019 (SCI-Expanded) identifier identifier identifier

Abstract

Aims: To compare the efficacy and safety of biphasic insulin aspart 30 (BIAsp 30) administered three times daily (TID) vs. twice daily (BID), plus metformin, in patients with type 2 diabetes mellitus (T2DM) inadequately controlled on basal insulin +/- 1 oral antidiabetic drug (OAD).